Cargando…
How imiquimod licenses plasmacytoid dendritic cells to kill tumors
We have provided evidence for a multifaceted antitumor-function of the Toll-like receptor 7 (TLR7) agonist imiquimod, which rapidly recruits plasmacytoid dendritic cells and possibly other immune cells into tumors by inducing the secretion of CCL2 by dermal cells. Imiquimod induces pDC maturation an...
Autores principales: | Holcmann, Martin, Drobits, Barbara, Sibilia, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525638/ https://www.ncbi.nlm.nih.gov/pubmed/23264929 http://dx.doi.org/10.4161/onci.22033 |
Ejemplares similares
-
License to kill: microsatellite instability and immune contexture
por: Maby, Pauline, et al.
Publicado: (2021) -
Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison
por: Conrad, Curdin, et al.
Publicado: (2013) -
Role of plasmacytoid dendritic cells in breast cancer bone dissemination
por: Sawant, Anandi, et al.
Publicado: (2013) -
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012) -
Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)